|Day Low/High||0.15 / 0.15|
|52 Wk Low/High||0.08 / 1.00|
The big lesson from the cases of Kenneth Starr and Arthur Samberg show that there is such a thing as too big to jail.
Report: Drugmaker Eli Lilly & Co. looks to acquire, but don't expect a mega-deal
Amylin Pharmaceuticals nominates 2 new directors as Icahn, others try to replace board members
Report: Nycomed, maker of Protonix, reportedly considering $13B sale
GenVec's shares sank Wednesday despite what the company said was a positive update on its experimental pancreatic cancer drug TNFerad.
Five of my stocks are trading at good long-term valuations, and I'm going to be opportunistic here.
With the Dow taking another tumble again, I am going to jump on the opportunity to add to some of my core holdings.
The $70-a-share offer represents a 51% premium to ImClone's closing stock price July 31, when a Bristol-Myers' offer came to light.
Smaller companies could learn a lot from Big Pharma's constant focus on the future.
King Pharmaceuticals bucks an otherwise dismal day in health stocks.
Genentech shares drop on investor concerns about financing for the company's deal with Roche but ease off their lows by the closing bell.
The Dow, which sank as much as 800 points earlier, stages a late-day rally to end the session down 3.6%. Frank Curzio breaks down the action in The Real Story video (above).
The Dow, which sank as much as 800 points earlier, remains below 10,000, but has eased off its worst session lows.
The Dow sinks 7.6%, and the S&P and Nasdaq plummet more than 6% after fearful investors send stocks down around the world.
Biotech stocks were falling along with the broader market Monday, but confirmation of Eli Lilly's bid lifted ImClone shares.
The Dow sinks 5%, and the S&P and Nasdaq plummet more than 6% after fearful investors send stocks down around the world.
The agreement, which values ImClone at $70 a share, has been approved by the boards of both ImClone and Eli Lilly.
The Dow falls along with the other major indices on Wall Street Monday following dismal stock performances in Asia and Europe.